Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H21N.ClH |
| Molecular Weight | 191.741 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNC(C)CC1CCCCC1
InChI
InChIKey=WLEGHNSHAIHZPS-UHFFFAOYSA-N
InChI=1S/C10H21N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h9-11H,3-8H2,1-2H3;1H
Propylhexedrine is considered to be an agonist of alpha-adrenergic receptors. It is effective as a topical vasoconstrictor. The primary medicinal use of Benzedrex (Propylhexedrine inhaler) propylhexedrine is temporary symptomatic relief of nasal decongestion due to colds, allergies and allergic rhinitis. Structurally and pharmacologically related to amphetamine.Exact mechanism of action unknown but thought to be similar to amphetamine. When used as a nasal inhaler for this indication, propylhexedrine reduces nasal airway resistance without producing rebound congestion. Abuse does not occur by nasal inhalation; however, a small amount of abuse of the propylhexedrine containing nasal inhalers occurs by oral ingestion of the contents of the inhaler or by intravenous injection. Propylhexedrine is a central nervous system (CNS) stimulant of low abuse potential, a stimulant of low preference for stimulant abusers compared with amphetamine, methylphenidate, phenmetrazine.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095203 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Benzedrex Approved UseSelf-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other allergies. Reduce swelling and facilitate visualization of nasal and pharyngeal membranes prior to surgery or diagnostic procedures. Open obstructed eustachian ostia in patients with ear inflammation. Launch Date1948 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/benzedrex.html
The Benzedrex propylhexedrine inhaler delivers 0.4–0.5 mg of the drug in each 800 mL of air. Adult dosage: 2 inhalations (0.4–0.5 mg) in each nostril no more than every 2 hours.
Route of Administration:
Nasal
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
102541
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
m9242
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
236461
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
213-753-7
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
27110
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
C084814
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
DTXSID70873945
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
064LUN7NZ5
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
1007-33-6
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY | |||
|
6192-95-6
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
SUPERSEDED | |||
|
170998
Created by
admin on Mon Mar 31 17:52:01 GMT 2025 , Edited by admin on Mon Mar 31 17:52:01 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD